Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapeutics for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company is advancing a pipeline that includes candidates for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), aiming to address unmet medical needs in rare muscle disorders. Dyne is recognized for its innovative approach to oligonucleotide delivery and its leadership in the neuromuscular disease market.
Company Facts
- Headquarters: Waltham, United States
- Founded: 2018
- Employees: 187
- Type: Public Corporation
- Website: https://www.dyne-tx.com
- Industries: Biotechnology, Pharmaceuticals, Rare Diseases, Neuromuscular Disorders